<DOC>
	<DOCNO>NCT00826852</DOCNO>
	<brief_summary>The purpose study : - ass efficacy combination term Objective ( clinical radiological ) Response Rate - ass time progression disease ; ass safety profile combination , assess survival time .</brief_summary>
	<brief_title>Weekly Docetaxel Four Weekly Carboplatin Non-small Cell Lung Cancer Carbo-Tax</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically/cytologically confirm inoperable locally advanced metastatic nonsmall cell lung cancer ECOG Performance Status 02 At least one measurable lesion two dimension mean CT scan No brain metastases No prior chemotherapy malignancy , Acceptable hematological profile ( define leukocyte count ≥ 3000/mm3 , platelet count ≥ 100.000mm3 Hb ≥ 9g/100mL ) , adequate renal function ( define serum creatinine ≤ 1.5mg/dl creatinine clearance measure 24 hour urine ≥ 60 mL/min ) , hepatic function ( define bilirubin ≤ 1.5 x maximum normal value even hepatic metastasis ; transaminase ( ALT , AST ) ≤ 2.5 x maximum normal value ; alkaline phosphatase ≤ 2.5 x maximum normal value , except case bone metastasis ) Concomitant use another anticancer therapy Chemotherapy , radiotherapy curative surgery Evidence intracerebral metastasis Unstable medical condition make patient take part clinical study ( congestive heart failure , serious arrhythmia , uncontrolled diabetes mellitus ) , history myocardial infarction within last 3 month , massive pleural peritoneal effusion ; presence serious uncontrolled infection , diarrhea , ileus , interstitial pneumonia , pulmonary fibrosis . Presence tumours different basal cell carcinoma skin , disease free survival le 3 year . Pregnancy breastfeed . In woman childbearing potential men , adequate contraceptive method must use Social psychological condition render patient inadequate followup study Contraindication study drug ( e.g . history hypersensitivity ingredient study drug ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>